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Targeting host factors is a complementary strat-
egy for the development of new antiviral drugs.
We screened a library of isoxazolidine and isox-
azole sulfonamides and found four compounds
that inhibited HIV-1 infection in human CD4+
lymphocytic T cells with no toxicity at IC90
concentrations. Structure-activity relationship
showed that benzyl sulfonamides and a halo-
substituted aromatic ring on the heterocycle
scaffold were critical for antiretroviral activity.
The size and position of the incorporated halo-
gen had a marked effect on the antiretroviral
activity. The sulfonamide derivatives had no sig-
niﬁcant effect on HIV-1 entry, reverse transcrip-
tion and integration but impaired a step
necessary for activation of viral gene expression.
This step was Tat-independent, strongly suggest-
ing that the target is a cell factor. A virus par-
tially resistant to the least potent compounds
could be selected but could not be propagated in
the long term, consistent with the possibility
that HIV-1 may be less likely to develop resis-
tance against drugs targeting some host factors.
Here, we provide evidence that novel synthetic
methods can be applied to develop small mole-
cules with antiretroviral activity that target host
factors important for HIV-1 replication.
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An estimated 33.2 million people are infected with HIV-1, most of
them living in Sub-Saharan Africa (
a). There is no protective vaccine
for HIV-1; thus, prevention and antiviral drugs are the only means
to reduce virus transmission and replication. Several classes of anti-
retroviral drugs have been developed, which are effective at inhibit-
ing different steps of the HIV-1 life cycle. The use of these drugs
in combination, known as highly active antiretroviral therapy
(HAART), has substantially decreased morbidity and mortality from
HIV-1 infection (1).
A general problem is that HIV-1 rapidly acquires resistance, even to
multiple drugs, by mutation, which leads to treatment failure in some
patients (2–4). The drug-resistant viruses can still transmit and are
not necessarily less fit than drug-na ve viruses (2,3). Furthermore, res-
ervoirs of multi-drug-resistant HIV strains can persist undetected for
many years (5). Hence, a secondary epidemic of drug-resistant virus
may make currently available treatments less effective (4). For exam-
ple, recent analysis on HIV-1 variants in the UK has shown an
increase in the prevalence of drug-resistant HIV-1 strains (4,5). Fur-
thermore, most existing antiretroviral drugs have considerable side–
effects, and their availability in developing countries is limited. Thus,
the development of new classes of antiretroviral drugs is important.
A complementary, yet little explored, pharmacological approach to
inhibit virus replication is to target cellular factors necessary for infec-
tion (6). HIV-1, like all viruses, is a parasite that must exploit the cellu-
lar machinery to replicate. Thus, small molecules that prevent HIV-1
from interacting with such host factors may offer a valuable comple-
ment to the more classical approach based on inhibition of viral
enzymes. The chemokine receptor antagonists are one example of an-
tiviral drugs directed against cellular cofactors now in clinical use
(7,8). A possible advantage of this approach lies in the lower mutation
rate of cell factors compared to viral proteins; hence, viral mutants
resistant to the inhibitors may be less likely to emerge.
The potential value of this approach for antiviral drug development
is highlighted by three genome-wide, high throughput screens
based on small interfering RNA (siRNA) technology, which identified
several hundred host cell factors important for HIV replication
(9–11). Although such studies are clearly important, it is difficult to
predict which factors among the hundreds identified will be suscep-
tible to modulation by small molecules and whether they represent
a valid target for antiviral drug development.
Small molecules offer an alternative strategy for the identification
of 'druggable' cellular targets necessary for HIV replication. Thus,
by utilizing novel synthetic chemistry, it is possible to design inter-
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doi: 10.1111/j.1747-0285.2010.00956.xesting motifs, which are not generally available. If the chemistry is
amenable to a library format, then medium high throughput screen-
ing can be used to identify small molecules with antiviral pheno-
types that block specific steps of the viral life cycle. Once such
molecules have been discovered, they can then be utilized for the
identification of the targeted factor(s) (12,13), forming the basis for
a more focused rational drug design aimed at finding lead com-
pounds with greater antiviral potency and specificity. This experi-
mental approach may also reveal new and unanticipated cellular
pathways exploited by viruses to replicate.
Here, we describe the use of a new class of chemical entity, which
has led to the identification of new molecules with antiretroviral
activity that target host components important for specific steps of
the viral life cycle. We describe the specific functional groups
required for antiretroviral activity and provide evidence that HIV-1
may not easily escape the effect of small molecules targeting some
host components.
Methods and Materials
Chemistry
Isoxazolidines 1a-h, 1j, 1m and 1n were prepared as previously
described, and isoxazolidines 1i, 1k, 1l and 1o–y were prepared
in an analogous fashion (14). Isoxazoles 2a–c, 2j and 2k were
prepared as previously described, and isoxazoles 2d–h and 2l
were prepared in an analogous fashion (15).
(3R*,4R*)-3-(4-bromophenyl)-2-methyl-N-(4-methylbenzyl)-1,2-
oxazolidine-4-sulfonamide (1i): Rf 0.31 (2:1 Et2O⁄petroleum ether
40–60  C); mp 112–113  C; IR (thin film) 3284, 2920, 2873, 1736,
1592, 1515, 1488, 1324, 1146, 686 cm
)1;
1H NMR (500 MHz, CDCl3)
d 7.47 (2 H, d, J = 8.2 Hz), 7.26 (2 H, d, J = 8.2 Hz), 7.07 (2 H, d,
J = 7.7 Hz), 6.96 (2 H, d, J = 7.7 Hz), 5.04 (1 H, t, J = 5.5 Hz), 4.30
(1 H, dd, J = 9.7, 3.3 Hz), 4.15–4.19 (1 H, dd, J = 9.7, 8.5 Hz), 4.11
(1 H, dd, J = 13.8, 5.5 Hz), 3.97 (1 H, dd, J = 13.8, 5.5 Hz),
3.76–3.80 (2 H, m), 2.56 (3 H), 2.32 (3 H, s);
13C NMR (125 MHz,
CDCl3) d 138.04 (s), 136.15 (s), 133.22 (s), 132.16 (d), 129.93
(d), 129.37 (d), 128.21 (d), 122.80 (s), 73.55 (d), 72.10 (d),
66.97 (t), 47.14 (t), 42.76 (q), 21.22 (q); LRMS (EI) 426 (M
+Æ, 7%),
424 (M
+Æ, 6), 240 (100), 238 (95), 214 (14), 212 (16), 116 (43);
HRMS (EI) calcd for C18H21BrN2O3S( M
+Æ) 424.0450, observed
424.0447.
(3R*,4R*)-2-methyl-N-(4-methylbenzyl)-3-phenyl-1,2-
oxazolidine-4-sulfonamide (1j): Rf 0.29 (2:1 Et2O⁄petro-
leum ether 40–60  C); mp 96–98  C; IR (thin film) 3300, 2922,
2856, 1589, 1456, 1414, 1319, 1144, 1034, 856 cm
)1;
1H NMR
(300 MHz, CDCl3) d 7.48 (2 H, d, J = 8.0 Hz), 7.27 (2 H, d,
J = 8.0 Hz), 7.08 (2 H, d, J = 7.7 Hz), 6.96 (2 H, d, J = 7.7 Hz), 4.91
(1 H, br t, J = 5.6 Hz), 4.29–4.33 (1 H, m), 4.09–4.21 (2 H, m), 3.98
(1 H, dd, J = 13.9, 5.6 Hz), 3.76–3.82 (2 H, m), 2.58 (3 H, s), 2.33
(3 H, s);
13C NMR (75 MHz, CDCl3) d 138.0 (s), 136.1 (s), 133.1 (s),
132.1 (d), 129.8 (d), 129.5 (d), 128.0 (d), 122.8 (s), 73.6 (d), 73.5 (d),
66.9 (t), 47.1 (t), 42.7 (q), 21.2 (q); LRMS (EI) 426 (M
+, 6%), 424
(M
+, 8), 240 (63), 197 (28), 120 (100); HRMS (EI) calcd for
C18H21BrN2O3S( M
+Æ) 424.0456, observed 424.0450.
(3R*,4R*)-3-(2-bromophenyl)-2-methyl-N-(4-methylb-
enzyl)-1,2-oxazolidine-4-sulfonamide (1k): Rf 0.25 (2:1
Et2O⁄petroleum ether 40–60  C); IR (thin film) 3251, 2978, 1737,
1433, 1328, 1148, 698 cm
)1;
1H NMR (500 MHz, CDCl3) d 7.59 (1
H, dd, J = 7.6, 1.1 Hz), 7.48 (1 H, d, J = 7.6 Hz), 7.38 (1 H, t,
J = 7.6 Hz), 7.24 (1 H, t, J = 7.6 Hz), 7.01 (2 H, d, J = 7.7 Hz), 6.88
(2 H, d, J = 7.7 Hz), 4.60 (1 H, t, J = 5.7 Hz), 4.50 (1 H, d,
J = 6.9 Hz), 4.46 (1 H, dd, J = 9.8, 3.6 Hz), 4.36 (1 H, dd, J = 9.8,
8.5 Hz), 4.13 (1 H, dd, J = 13.6, 5.7 Hz), 3.95 (1 H, td, J = 8.5,
3.6 Hz), 3.77 (1 H, dd, J = 13.6, 5.7 Hz), 2.64 (3 H, s), 2.30 (3 H, s);
13C NMR (125 MHz, CDCl3) d 137.92 (s), 133.36 (d), 132.92 (s),
130.20 (d), 130.10 (d), 129.50 (d), 128.49 (s), 127.98 (d), 127.42 (d),
124.79 (s), 73.12 (d), 71.65 (d), 67.19 (t), 47.29 (t), 46.83 (q), 21.19
(q); LRMS (EI) 426 (M
+Æ, 4%), 424 (M
+Æ, 4), 240 (39), 197 (10), 120
(17), 105 (17); HRMS (EI) calcd for C18H21BrN2O3S( M
+Æ) 424.0450,
observed 424.0446.
(3R*,4R*)-3-(2-chlorophenyl)-2-methyl-N-(4-methylben-
zyl)-1,2-oxazolidine-4-sulfonamide (1l): Rf 0.25 (2:1
Et2O⁄petroleum ether 40–60  C); IR (thin film) 3283, 2922, 1737,
1438, 1328, 1148, 704 cm
)1;
1H NMR (500 MHz, CDCl3) d 7.49 (1
H, d, J = 7.3 Hz), 7.40 (1 H, dd, J = 7.4, 1.9 Hz), 7.33 (2 H, m), 7.05
(2 H, J = 7.9 Hz), 7.02 (2 H, d, J = 7.9 Hz), 4.54 (1 H, t, J = 5.8 Hz),
4.48 (1 H, d, J = 8.2 Hz), 4.45 (1 H, dd, J = 9.8, 3.8 Hz), 4.35 (1 H,
dd, J = 9.8, 8.5 Hz), 4.13 (1 H, dd, J = 13.5, 5.7 Hz), 3.97 (1 H, td,
J = 8.5, 3.8 Hz), 3.80 (1 H, dd, J = 13.5, 5.8 Hz), 2.63 (3 H, s), 2.30
(3 H, s);
13C NMR (125 MHz, CDCl3) d 137.95 (s), 134.45 (s), 134.31
(s), 132.96 (s), 130.11 (d), 129.88 (d), 129.52 (d), 127.96 (d), 127.87
(d), 127.33 (d), 72.96 (d), 70.18 (d), 67.16 (t), 47.31 (t), 42.91 (q),
21.18 (q); LRMS (CI) 383 ((M+H)
+, 34%), 381 ((M+H)
+, 100), 197 (17),
195 (50), 120 (14); HRMS (CI) calcd for C18H22ClN2O3S ((M+H)
+)
381.1039, observed 381.1045.
(3R*,4R*)-N-tert-butyl-3-(4-methoxyphenyl)-2-methyl-1,2-
oxazolidine-4-sulfonamide (1o): Rf 0.18 (2:1 Et2O⁄petroleum
ether 40–60  C); mp 133–137  C; IR (neat) 3280, 2961, 1614, 1516,
1435, 1305, 1252, 1138, 1010, 867 cm
)1;
1H NMR (300 MHz, CDCl3)
d 7.37 (2 H, d, J = 8.7 Hz), 6.91 (2 H, d, J = 8.7 Hz), 4.57 (1 H, s),
4.41 (1 H, dd, J = 9.7, 3.8 Hz), 4.32 (1 H, dd, J = 9.7, 8.6 Hz), 3.97
(1 H, td, J = 8.0, 3.8 Hz), 3.81 (3 H, s), 3.72 (1 H, br d, J = 7.5 Hz),
2.60 (3 H, s), 1.08 (9 H, s);
13C NMR (75 MHz, CDCl3) d 159.9 (s),
129.7 (d), 129.0 (s), 114.3 (d), 75.2 (d), 74.6 (d), 67.0 (t), 55.3 (q),
55.0 (s), 42.6 (q), 30.0 (q); LRMS (EI) 328 (M
+, 21), 190 (100), 147
(32); HRMS (EI): calcd for C15H24N2O4S( M
+) 328.1457, found
328.1449.
(3R*,4R*)-N-tert-butyl-3-(3-chlorophenyl)-2-methyl-
1,2-oxazolidine-4-sulfonamide (1p): Rf 0.27 (2:1
Et2O⁄petroleum ether 40–60  C); mp 117–119  C; IR 3322, 2963,
2873, 1575, 1479, 1426, 1316, 1133, 1040, 986, 833, 797 cm
)1;
1H
NMR (300 MHz, CDCl3) d 7.49 (1 H, s), 7.31–7.39 (3 H, m), 4.73 (1
H, s), 4.41 (1 H, dd, J = 9.7, 3.7 Hz), 4.31 (1 H, dd, J = 9.7, 8.4 Hz),
3.94 (1 H, td, J = 8.1, 3.7 Hz), 3.79 (1 H, d, J = 7.3 Hz), 2.64
(3 H, s), 1.12 (9 H, s);
13C NMR (75 MHz, CDCl3) d 139.8 (s), 134.7
(s), 130.2 (d), 128.9 (d), 128.5 (d), 126.7 (d), 75.6 (d), 74.1 (d), 67.1
(t), 55.2 (s), 42.8 (q), 30.0 (q); LRMS (EI) 334 (M
+, 4%), 332 (M
+, 12),
194 (100), 115 (25); HRMS (EI): calcd for C14H21ClN2O3S( M
+)
332.0961, found 332.0974.
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1,2-oxazolidine-4-sulfonamide (1q): Rf 0.24 (2:1
Et2O⁄petroleum ether 40–60  C); mp 164–168  C; IR (neat) 3267,
2921, 1493, 1307, 1141, 1091, 1012, 816 cm
)1;
1H NMR (300 MHz,
CDCl3) d 7.42 (2 H, d, J = 8.5 Hz), 7.36 (2 H, d, J = 8.5 Hz), 4.85 (1
H, s), 4.40 (1 H, dd, J = 9.7, 3.7 Hz), 4.31 (1 H, dd, J = 9.7, 8.3 Hz),
3.93 (1 H, app. td, J = 7.9, 3.7 Hz), 3.78 (1 H, br d, J = 7.3 Hz),
2.61 (3 H, s), 1.12 (9 H, s);
13C NMR (75 MHz, CDCl3) d 136.0 (s),
134.5 (s), 129.8 (d), 129.1 (d), 75.6 (d), 74.1 (d), 67.1 (t), 55.1 (s),
42.7 (q), 30.0 (q); LRMS (EI) 334 (M
+, 10%), 332 (M
+, 27), 194 (100),
174 (39), 151 (26), 115 (33); HRMS (EI): calcd for C14H21ClN2O3S
(M
+Æ) 332.0961, found 332.0976.
(3R*,4R*)-N-(2-hydroxyethyl)-2-methyl-3-phenyl-1,2-
oxazolidine-4-sulfonamide (1r): Rf 0.15 (2:1 EtOAc⁄petro-
leum ether 40–60  C); IR 3480, 3279, 2921, 1456, 1311, 1144,
1039, 934, 887 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.33–7.47 (5 H,
m), 5.53 (1 H, t, J = 6.2 Hz), 4.38 (1 H, dd, J = 9.9, 4.3 Hz), 4.43 (1
H, dd, J = 9.9, 7.8 Hz), 4.08 (1 H, td, J = 7.4, 4.3 Hz), 3.82 (1 H, br
d, J = 6.4 Hz), 3.43–3.56 (2 H, m), 3.08 (1 H, ddt, J = 12.6, 6.2,
3.9 Hz), 2.84–2.96 (1 H, m), 2.69 (1 H, br s), 2.62 (3 H, s);
13C NMR
(75 MHz, CDCl3) d 136.8 (s), 129.0 (d), 128.8 (d), 128.3 (d), 74.4 (d),
73.1 (d), 67.0 (t), 61.6 (t), 45.4 (t), 42.7 (q); LRMS (EI) 286 (M
+Æ,
11%), 160 (100), 117 (48); HRMS (EI): calcd for C12H18N2O4S( M
+Æ)
286.0987, found 286.0981.
(3R*,4R*)-N-(2-hydroxyethyl)-2-methyl-3-(naphthalen-
2-yl)-1,2-oxazolidine-4-sulfonamide (1s): Rf 0.33 (9:1
CHCl3⁄MeOH); IR 3457, 3284, 2923, 1509, 1435, 1314, 1144, 1040,
955 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.93 (1 H, s), 7.81–7.87
(3 H, m), 7.57 (1 H, dd, J = 8.6, 1.5 Hz), 7.49 (2 H, dt, J = 9.5,
3.6 Hz), 5.69 (1 H, br t, J = 5.8 Hz), 4.43 (1 H, dd, J = 10.0, 4.0 Hz),
4.38 (1 H, dd, J = 10.0, 7.6 Hz), 4.17 (1 H, app. td, J = 7.6, 4.0 Hz),
4.02 (1 H, br d, J = 6.6 Hz), 3.36–3.49 (2 H, m), 2.82–3.08 (3 H, m),
2.65 (3 H, s);
13C NMR (75 MHz, CDCl3) d 134.2 (s), 133.4 (s), 133.2
(s), 128.9 (d), 128.0 (2 · d), 127.8 (d), 126.6 (2 · d), 125.1 (d), 74.5
(d), 73.1 (d), 67.1 (t), 61.5 (t), 45.4 (t), 42.8 (q); LRMS (EI) 336 (M
+Æ,
24%), 210 (100), 184 (23), 167 (58), 152 (33), 127 (20); HRMS (EI):
calcd for C16H20N2O4S( M
+) 336.1144, found 336.1138.
(3R*,4R*)-3-(5-bromofuran-2-yl)-2-methyl-N-(4-meth-
ylbenzyl)-1,2-oxazolidine-4-sulfonamide (1t): Rf 0.27
(2:1 Et2O⁄petroleum ether 40–60  C); IR (thin film) 3142, 2919,
1441, 1320, 1141, 1020, 901, 793 cm
)1;
1H NMR (300 MHz, CDCl3)
d 7.14 (2 H, d, J = 8.0 Hz), 7.08 (2 H, d, J = 8.0 Hz), 6.37 (1 H, d,
J = 3.5 Hz), 6.31 (1 H, d, J = 3.5 Hz), 4.81 (1 H, br s), 4.33 (1 H, dd,
J = 9.1, 3.2 Hz), 4.05–4.24 (4 H, m), 3.89 (1 H, br s), 2.67 (3 H, s),
2.34 (3 H, s);
13C NMR (75 MHz, CDCl3) d 150.6 (s), 138.1 (s), 133.1
(s), 129.6 (d), 128.0 (d), 123.0 (s), 113.8 (d), 112.6 (d), 69.4 (d), 67.5
(d), 66.8 (t), 47.2 (t), 42.8 (q), 21.2 (q); LRMS (EI) 416 (M
+Æ, 7%), 414
(M
+, 7), 230 (100), 187 (52), 159 (22), 120 (95); HRMS (EI) calcd for
C16H19BrN2O4S( M
+) 414.0194, observed 414.0206.
(3R*,4R*)-3-(4-ﬂuorophenyl)-2-methyl-N-(4-methylben-
zyl)-1,2-oxazolidine-4-sulfonamide (1u): Rf 0.29 (2:1
Et2O⁄petroleum ether 40–60  C); mp 129–132  C; IR (thin film)
3284, 2923, 2874, 1606, 1510, 1324, 1146, 841 cm
)1;
1H NMR
(500 MHz, CDCl3) d 7.37 (2 H, d, J = 8.5 Hz), 7.07 (2 H, d,
J = 8.0 Hz), 7.03 (2 H, d, J = 8.5 Hz), 6.97 (2 H, d, J = 8.0 Hz), 4.93
(1 H, t, J = 5.3 Hz), 4.31 (1 H, dd, J = 9.7, 3.3 Hz), 4.19 (1 H, dd,
J = 9.7, 7.8 Hz), 4.11 (1 H, dd, J = 13.5, 5.3 Hz), 3.96 (1H, dd,
J = 13.5, 5.3 Hz), 3.79–3.84 (2 H, m), 2.57 (3 H, s), 2.31 (3 H, s);
13C NMR (125 MHz, CDCl3) d 162.94 (s, JCF = 248.6 Hz), 138.02 (s),
133.26 (s), 132.79 (s, JCF = 2.9 Hz), 129.95 (d, JCF = 8.6 Hz), 129.56
(d), 128.02 (d), 115.98 (d, JCF = 22.1 Hz), 73.58 (d), 72.16 (d), 66.93
(t), 74.63 (t), 42.69 (q), 21.17 (q); LRMS (EI) 364 (M
+, 8%), 178 (100),
135 (30); HRMS (EI) calcd for C18H21FN2O3S( M
+) 364.1251,
observed 364.1246.
(3R*,4R*)-3-(4-chlorophenyl)-2-methyl-N-(4-methylben-
zyl)-1,2-oxazolidine-4-sulfonamide (1v): Rf 0.29 (2:1
Et2O⁄petroleum ether 40–60  C); IR (thin film) 3285, 2922, 2874,
1736, 1599, 1515, 1492, 1323, 1145, 736 cm
)1;
1H NMR (500 MHz,
CDCl3) d 7.31–7.34 (4 H, m), 7.07 (2 H, d, J = 8.0 Hz), 6.96 (2 H, d,
J = 8.0 Hz), 5.00 (1 H, t, J = 5.5 Hz), 4.30 (1 H, dd, J = 9.7, 3.3 Hz),
4.18 (1 H, dd, J = 9.7, 7.9 Hz), 4.11 (1 H, dd, J = 13.8, 5.6 Hz), 3.97
(1H, dd, J = 13.8, 5.5 Hz), 3.77–3.82 (2 H, m), 2.57 (3 H, s), 2.32 (3
H, s);
13C NMR (125 MHz, CDCl3) d 137.93 (s), 135.62 (s), 134.63
(s), 133.23 (s), 129.56 (d), 129.21 (d), 128.89 (d), 128.02 (d), 73.59
(d), 72.16 (d), 66.97 (t), 47.51 (t), 42.76 (q), 21.20 (q); LRMS (EI) 382
(M
+Æ, 2%), 380 (M
+, 5), 196 (38), 194 (100), 178 (25), 151 (42), 120
(51); HRMS (EI) calcd for C18H21ClN2O3S( M
+) 380.0956, observed
380.0963.
(3R*,4R*)-3-(4-iodophenyl)-2-methyl-N-(4-methylben-
zyl)-1,2-oxazolidine-4-sulfonamide (1w): Rf 0.27 (2:1
Et2O⁄petroleum ether 40–60  C); mp 132–134  C; IR (thin film)
3283, 2956, 2899, 1737, 1515, 1327, 1148 cm
)1;
1H NMR
(500 MHz, CDCl3) d 7.68 (2 H, d, J = 8.3 Hz), 7.13 (2 H, d,
J = 8.3 Hz), 7.07 (2 H, d, J = 7.9 Hz), 6.95 (2 H, d, J = 7.9 Hz), 4.97
(1 H, t, J = 5.6 Hz), 4.30 (1 H, d, J = 9.7 Hz), 4.17 (1 H, dd, J = 9.7,
3.3 Hz), 4.10 (1 H, dd, J = 13.8, 5.6 Hz), 3.96 (1 H, dd, J = 13.8,
5.6 Hz), 3.74–3.81 (2 H, m,), 2.56 (3 H, s), 2.32 (3 H, s);
13C NMR
(125 MHz, CDCl3) d 138.13 (d), 136.83 (s), 132.89 (s), 129.90 (d),
129.60 (d), 128.90 (s), 128.21 (d), 94.55 (s), 73.74 (d), 73.51 (d),
66.97 (t), 47.51 (t), 42.80 (q), 21.26 (q); LRMS (EI) 472 (M
+Æ, 5%),
286 (100), 260 (12), 120 (30); HRMS (EI) calcd for C18H21IN2O3S( M
+)
472.0312, observed 472.0309.
(3R*,4R*)-3-(2-ﬂuorophenyl)-2-methyl-N-(4-methylben-
zyl)-1,2-oxazolidine-4-sulfonamide (1x): Rf 0.29 (2:1
Et2O⁄petroleum ether 40–60  C); IR (thin film) 3286, 2924, 2877,
1737, 1617, 1588, 1518, 1327, 1146, 844 cm
)1;
1H NMR (500 MHz,
CDCl3) d 7.41 (1 H, t, J = 7.1 Hz), 7.33–7.38 (1 H, m), 7.18 (1 H, d,
J = 7.1 Hz), 7.07 (1H, t, J = 7.1 Hz), 7.04 (2 H, d, J = 7.9 Hz), 6.95
(2 H, d, J = 7.9 Hz), 4.85 (1 H, t, J = 5.3 Hz), 4.38 (1 H, dd, J = 9.7,
3.5 Hz), 4.27 (1 H, dd, J = 9.7, 8.3 Hz), 4.14 (1 H, dd, J = 13.7,
5.3 Hz), 4.11 (1 H, d, J = 3.5 Hz), 4.02 (1 H, d, J = 3.5 Hz), 3.94 (1
H, dd, J = 13.7, 5.2 Hz), 2.60 (3 H, s), 2.30 (3 H, s);
13C NMR
(125 MHz, CDCl3) d 161.08 (s, JCF = 248.6 Hz), 137.89 (s), 113.94 (s),
130.50 (d, JCF = 8.6 Hz), 129.93 (d, JCF = 3.8 Hz), 129.51 (d), 127.99
(d), 124.99 (d, JCF = 3.8 Hz), 123.70 (s, JCF = 10.6 Hz), 116.16 (d,
JCF = 22.1 Hz), 72.23 (d), 68.12 (d), 67.08 (t), 47.51 (t), 42.90
(q), 21.16 (q); LRMS (CI) 365 ((M+H)
+, 100%), 178 (24), 120 (4);
HRMS (CI) calcd for C18H22FN2O3S ((M+H)
+) 365.1335, observed
365.1345.
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zyl)-1,2-oxazolidine-4-sulfonamide (1y): Rf 0.27 (2:1
Et2O⁄petroleum ether 40–60  C); IR (thin film) 3310, 2922, 2874,
1736, 1515, 1432, 1326, 1147 cm
)1;
1H NMR (500 MHz, CDCl3) d
7.87 (1 H, d, J = 7.9 Hz), 7.40 (2 H, d, J = 7.9 Hz), 7.06–7.10 (1 H,
m), 7.01 (2 H, J = 7.9 Hz), 6.89 (2 H, d, J = 7.9 Hz), 4.70 (1 H, t,
J = 5.8 Hz), 4.44 (1 H, d, J = 9.8 Hz), 4.38 (1 H, d, J = 7.1 Hz), 4.34
(1 H, dd, J = 9.8, 8.3 Hz), 4.13 (1 H, dd, J = 13.5, 5.9 Hz), 3.91 (1 H,
t, J = 8.2 Hz), 3.78 (1 H, dd, J = 13.5, 5.8 Hz), 2.64 (3 H, s), 2.30 (3
H, s);
13C NMR (125 MHz, CDCl3) d 140.07 (d), 139.14 (s), 137.89 (s),
132.96 (s), 130.49 (d), 129.79 (d), 129.50 (d), 129.26 (d), 128.03 (d),
101.18 (s), 76.85 (d), 73.43 (d), 67.24 (t), 47.28 (t), 42.55 (q), 21.20 (q);
LRMS (CI) 473 ((M+H)
+, 100%), 287 (52), 120 (20), 105 (18); HRMS
(CI) calcd for C18H22IN2O3S ((M+H)
+) 473.0395, observed 473.0403.
3-(3-chlorophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2d): Rf 0.08 (20% Et2O⁄petroleum ether 40–
60  C); mp 101–104  C; IR (thin film) 3363, 3055, 2985, 1575,
1172 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.74 (1 H, s), 7.62 (1 H, d,
J = 6.7 Hz), 7.46 (1 H, t, J = 6.7 Hz), 7.41 (1 H, d, J = 6.9 Hz), 7.14
(2 H, d, J = 7.0 Hz), 7.08 (2 H, d, J = 7.0 Hz), 6.91 (1 H, s), 5.43 (1
H, br s), 4.34 (2 H, s), 2.22 (3 H, s);
13C NMR (75 MHz, CDCl3) d
166.9 (s), 161.4 (s), 138.5 (s), 135.2 (s), 132.1 (s), 130.9 (d), 130.5
(d), 129.5 (d), 129.0 (s), 128.1 (d), 127.0 (d), 125.0 (d), 105.8 (d), 47.4
(t), 21.0 (q); LRMS (FAB) 365 ((M+H)
+, 13%), 363 ((M+H)
+, 40), 289
(12), 154 (100); HRMS (FAB) calcd for C17H16ClN2O3S ((M+H)
+)
363.0570, observed 363.0576.
3-(2-chlorophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2e): Rf 0.06 (20% Et2O⁄petroleum ether 40–
60  C); mp 84–86  C; IR (thin film) 3300, 3055, 1353, 1170 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.68 (1 H, dd, J = 7.3, 1.9 Hz), 7.52 (1
H, dd, J = 7.3, 1.9 Hz), 7.44 (1 H, td, J = 7.3, 2.1 Hz), 7.37 (1 H, td,
J = 7.4, 2.0 Hz), 7.15 (2 H, d, J = 8.1 Hz), 7.15 (1 H, s), 7.08 (2 H,
d, J = 8.1 Hz), 5.65 (1 H, t, J = 5.9 Hz), 4.35 (2 H, d, J = 6.0 Hz),
2.25 (3 H, s);
13C NMR (75 MHz, CDCl3) d 165.9 (s), 161.1 (s), 138.0
(s), 132.9 (s), 132.3 (s), 131.7 (d), 131.0 (d), 130.6 (d), 129.5 (d),
128.0 (d), 127.3 (d), 126.6 (s), 108.8 (d), 47.4 (t), 21.0 (q); LRMS
(FAB) 365 ((M+H)
+, 30%), 363 ((M+H)
+, 86), 307 (34), 289 (18), 165
(100); HRMS (FAB) calcd for C17H16ClN2O3S ((M+H)
+) 363.0570,
observed 363.0573.
3-(4-bromophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2f): Rf 0.06 (20% Et2O⁄petroleum ether 40–
60  C); mp 156–158  C; IR (thin film) 3373, 3053, 2985, 1170 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.63 (4 H, s), 7.15 (2 H, d, J = 8.1 Hz),
7.09 (2 H, d, J = 8.1 Hz), 6.93 (1 H, s), 5.25 (1 H, t, J = 5.9 Hz),
4.34 (2 H, d, J = 5.9 Hz), 2.24 (3 H, s);
13C NMR (75 MHz, CDCl3) d
166.1 (s), 161.3 (s), 138.2 (s), 132.5 (d), 132.2 (s), 129.5 (d), 128.3
(d), 128.0 (d), 125.0 (s), 114.7 (s), 105.7 (d), 47.5 (t), 21.0 (q); LRMS
(FAB) 409 ((M+H)
+, 26%), 407 ((M+H)
+, 26), 307 (17), 286 (33), 154
(100); HRMS (FAB) calcd for C17H16BrN2O3S (M+H)
+ 407.0065,
observed 407.0048.
3-(3-bromophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2g): Rf 0.06 (20% Et2O⁄petroleum ether 40–
60  C); mp 101–103  C; IR (thin film) 3367, 3055, 2985, 1326,
1172 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.89 (1 H, s), 7.61–7.68 (2
H, m), 7.36 (1 H, t, J = 7.8 Hz), 7.14 (2 H, d, J = 7.8 Hz), 7.08 (2 H,
d, J = 7.8 Hz), 6.90 (1 H, s), 5.47 (1 H, br s), 4.34 (2 H, s), 2.22 (3
H, s);
13C NMR (75 MHz, CDCl3) d 166.9 (s), 161.3 (s), 138.2 (s),
133.8 (d), 132.1 (s), 130.7 (d), 129.9 (d), 129.5 (d), 129.3 (s), 128.1
(d), 125.5 (d), 123.2 (s), 105.7 (d), 47.4 (t), 21.0 (q); LRMS (FAB) 409
((M+H)
+, 44%), 407 ((M+H)
+, 46), 307 (15), 154 (100); HRMS (FAB)
calcd for C17H16BrN2O3S ((M+H)
+) 407.0065, observed 407.0060.
3-(2-bromophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2h): Rf 0.10 (20% Et2O⁄petroleum ether 40–
60  C); mp 102–104  C; IR (thin film) 3365, 2052, 2985, 1170 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.70 (1 H, dd, J = 7.6, 1.8 Hz), 7.61 (1
H, dd, J = 7.6, 1.8 Hz), 7.44 (1H, td, J = 7.5, 1.8 Hz), 7.36 (1H, td,
J = 7.6, 2.1 Hz), 7.15 (1 H, s), 7.15 (2 H, d, J = 8.2 Hz), 7.10 (2 H, d,
J = 8.2 Hz), 5.47 (1 H, t, J = 5.8 Hz), 4.36 (2 H, d, J = 5.8 Hz), 2.29
(3 H, s);
13C NMR (75 MHz, CDCl3) d 165.7 (s), 162.5 (s), 138.1 (s),
133.8 (d), 132.3 (s), 131.8 (d), 131.4 (d), 129.5 (d), 128.7 (s), 122.2 (s),
127.9 (d), 127.8 (d), 108.9 (d), 47.4 (t), 21.1 (q); LRMS (FAB) 409
((M+H)
+, 91%), 407 ((M+H)
+, 100), 219 (30), 154 (36); HRMS (FAB)
calcd for C17H16BrN2O3S ((M+H)
+) 407.0065, observed 407.0061.
3-(2-ﬂuorophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2j): Rf 0.08 (20% Et2O⁄petroleum ether 40–
60  C); mp 111–113  C; IR (thin film) 3365, 3055, 2985, 1170 cm
)1;
1H NMR (300 MHz, CDCl3) d 7.96 (1 H, td, J = 5.8, 1.7 Hz), 7.50–
7.61 (1 H, m), 7.18–7.30 (2 H, m), 7.15 (2 H, d, J = 8.9 Hz), 7.12 (1
H, s), 7.09 (2 H, d, J = 8.9 Hz), 5.30 (1 H, t, J = 5.9 Hz), 4.34 (2 H,
d, J = 5.9 Hz), 2.24 (3 H, s);
13C NMR (125 MHz, CDCl3) d 166.44
(s), 160.1 (s, JCF = 252.6 Hz), 157.9 (s), 138.2 (s), 132.70 (s,
JCF = 8.5 Hz), 132.2 (s), 129.5 (d), 129.0 (d), 128.0 (d), 125.3 (d),
124.8 (d, JCF = 3.8 Hz), 116.6 (d, JCF = 21.4 Hz), 108.2 (d,
JCF = 9.7 Hz), 47.4 (t), 21.0 (q); LRMS (FAB) 347 ((M+H)
+, 100%),
251 (20), 154 (58); HRMS (FAB) calcd for C17H16FN2O3S ((M+H)
+)
347.0865, observed 347.0869.
3-(2-iodophenyl)-N-(4-methylbenzyl)-1,2-oxazole-5-
sulfonamide (2k): Rf 0.2 (20% Et2O⁄petroleum ether 40–
60  C); mp 115–117  C; IR (thin film) 3297, 1354, 1165 cm
)1;
1H
NMR (300 MHz, CDCl3) d 8.02 (1 H, dd, J = 7.5, 1.1 Hz), 7.52 (1 H,
td, J = 7.6, 1.1 Hz), 7.43 (1 H, dd, J = 7.5, 1.3 Hz), 7.24 (1 H, td,
J = 7.8, 1.1 Hz), 7.14 (2 H, d, J = 8.3 Hz), 7.09 (2 H, d, J = 8.3 Hz),
7.01 (1 H, s), 6.82 (1 H, t, J = 5.9 Hz), 4.28 (2 H, d, J = 5.9 Hz), 2.24
(3 H, s);
13C NMR (75 MHz, CDCl3) d 167.2 (s), 165.9 (s), 141.3 (d),
138.6 (s), 134.4 (s), 134.0 (s), 132.9 (d), 131.9 (d), 130.2 (d), 129.7 (d),
129.0 (d), 109.7 (d), 97.0 (s), 47.7 (t), 21.3 (q); LRMS (EI) 454 (M
+Æ,
22), 336 (20), 270 (44), 242 (55), 229 (86), 118 (86), 104 (100); HRMS
(EI) calcd for C17H16N2O3S( M
+Æ) 453.9846, observed 453.9864.
Cells and viruses
HeLa, HT1080 and 293T cells were grown in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal calf serum
(FCS) and 2 mM glutamine at 37  Ci n5 %C O 2. Jurkat, SupT1 and
C8166 cells were grown in RPMI medium supplemented with 10%
FCS at 37  C in 10% CO2. The HIV-1 vectors were made and purified
as described previously (16–18). HIV-1 NL4.3 (19) was produced by
Fugene transfection into 293T cells, and supernatant containing viral
particles was collected 48 h post transfection. Reverse transcriptase
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Tech, Uppsala, Sweden) following the manufacturer's instructions.
Infection assays
Approximately 4 · 10
5 adherent cells or 0.5 · 10
6 lymphocytic cells
were plated in 24-well plates in 500 lL of media incubated for 6 h
with the compounds and infected at a MOI of 0.05 using a VSV-G-
pseudotyped HIV-1 vector. Infected cells were incubated with the com-
pounds for 24 h, washed and analyzed by FACS. Total DNA was
extracted from an aliquot of infected cells and analyzed by Taqman
qPCR. In some experiments, one aliquot of infected cells was analyzed
24 h post infection and another aliquot 1 week later. For infection with
wild-type HIV-1 NL4.3, 0.5 · 10
6 lymphocytic cells were plated into
24-well plates in 500 lL of medium and cultured in the presence of the
compounds for 6 h. The culture was transferred to 96 U-well plates in
100 lL aliquots and infected at MOI of 0.1. Cells were grown for
48–72 h, washed once in serum-free medium, fixed in 50% methanol–
50% acetone for 2 min at )20  C and immunostained as previously
described (20) using anti-HIV-1 p24 Ab (38:96K and EF7 at 1:1 ratio,
AIDS Reagent Program) and secondary anti-mouse Abs conjugated to
b-galactosidase (Southern Biotechnology, Birmingham, AL, USA)
diluted 1⁄400. Alternatively, HIV-infected cells were fixed for 20 min
at room temperature in 100 lL 4% paraformaldehyde in PBS, washed
and permeabilized in 100 lL of cytofix⁄cytoperm solution (BD
Biosciences, San Jose, CA, USA) for 30 min at 4  C. The same primary
anti-p24 Ab was detected by an anti-mouse immunoglobulin FITC con-
jugated, diluted1⁄200,andcellswereanalyzedbyFACS.Macrophages
immunostained for p24 were counted using an MRX TC Revelation
microplate reader (Dynex Technologies, Chantilly, VA,USA).
Cell toxicity assays
For cell cycle profiling, 2 · 10
6 cells were resuspended in 50 lL
PBS + 3% FCS and fixed by addition of 1 mL cold 80% ethanol and
incubation at 4  C for 30 min. Cells were resuspended in 0.5 mL
PBS + 0.25% (v⁄v) NP-40 (IGEPAL CA-630) (Sigma, Gillingham,
Dorset, UK), 2 U of DNAse-free RNAse A (Roche, Welwyn Garden
City, UK), incubated for 30 min at 37  C and centrifuged. The
pellet was resuspended in 400 lL PBS + 0.1 lg propidium iodide
(Sigma) and analyzed by FACS. Cell viability was analyzed with the
LIVE⁄DEAD kit (Molecular Probes, Paisley, UK) following the manu-
facturers' instructions or by trypan blue staining.
Taqman qPCR and RT-qPCR
Approximately 1 · 10
6 cells were washed twice in PBS, and total
DNA was extracted with the Qiamp
  DNA Minikit (Qiagen, Crawley,
UK). Quantitative PCRs were carried out as previously described
(18,21) in 25 lL volume containing 100 ng total DNA using an ABI
Prism
  7000 Sequence Detection System (SDS). For mRNA quantifi-
cation, nucleic acids were extracted from 1 · 10
7 SupT1 cells using
the RNeasy Mini Kit (Qiagen) according to the manufacturer's
instructions. Samples were treated with 2 U⁄lg nucleic acids ReQ1
DNAse in 1· buffer (Promega, Southampton, UK) for 30 min at
37  C, then 2 mM EGTA were added to stop the reaction, and
samples were incubated at 60  C for 20 min. The Superscript III kit
(Invitrogen, Paisley, UK) was used for first-strand cDNA synthesis by
random hexamers following the manufacturer's instructions. Control
samples were incubated in parallel without RT. TaqMan quantitative
PCR was performed in an ABI Prism 7000 thermocycler with the GFP
primers⁄probe set (18), 2LTR (Long Terminal Repeat) circular DNA
primer set (21) and the GADPH RNA primers⁄probe set GADPH-F
GGCTGAGAACGGGAAGCTT, GADPH-RC AGGGATCTCGCTCCTGGAA,
probe FAM-TCATCAATGGAAATCCCATCACCA-TAMRA.
Sequencing of parental and resistant viruses
The sequences of parental and resistant NL4-3 viruses were obtained
by PCR amplification of 15 different overlapping segments covering
the entire viral genome. Total DNA was extracted from chronically
infected cells using the Qiagen DNA extraction Kit. The PCR was per-
formed in 50 lL containing 1· buffer (Promega), 33 pmol each pri-
mer, 0.5 lL Pfu DNA polymerase and 100 lM dNTPs using four
different annealing temperatures ranging from 45 to 65  C to select
the optimal conditions for each set of primers. The PCR products
were resolved on a 1% agarose gel and visualized by ethidium
bromide. The different sets of primers are specified below.
Primer Sequence (5¢-3¢)T AN ( C)
NL4-3 1F
NL4-3 1R
TGG AAG GGC TAA TTT GGT CCC
GAG AGA TCT CCT CTG GCT TTA CT
65
NL4-3 2F
NL4-3 2R
GCC CGT CTG TTG TGT GAC TCT G
GCA CTC TAT CCC ATT CTG CAG C
60
NL4-3 3F
NL4-3 3R
CAT TAT CAG AAG GAG CCA CCC
CTT CTT TGC CAC AAT TGA AAC A
65
NL4-3 4F
NL4-3 4R
ATG ATG ACA GCA TGT CAG GGA G
CAA CAG ATG TTG TCT CAG TTC CTC
60
NL4-3 5F
NL4-3 5R
CAG ATG ATA CAG TAT TAG AAG
CAA CAG ATG TTG TCT CAG TTC CTC
45
NL4-3 6F
NL4-3 6R
GGA TCA CCA GCA ATA TTC CAG TGT
CAG TTA CAT ATC CTG CTT TTC C
55
NL4-3 7F
NL4-3 7R
CTG GAT TCC TGA GTG GGA GTT T
GAG GAA GTA TGC TGT TTC TTG CCC
55
NL4-3 8F
NL4-3 8R
GTA GAC TGT AGC CCA GGA ATA TGG
TAC TAA TTT AGC ATC CCC TAG TGG
55
NL4-3 9F
NL4-3 9R
GTA GAC AGG ATG AGG ATT AAC ACA TGG
GAC TGT TCT GAT GAG CTC TTC GTC G
60
NL4-3 10F
NL4-3 10R
GTC AGC CTA AAA CTG CTT GTA CCA
GCA CCT TAT CTC TTA TGC TTG TGC TG
50
NL4-3 11F
NL4-3 11R
GAC TAG GTA GAA CAG ATG CAT GAG GA
GTC CCC TCC TGA GGA TTG CTT AAA G
60
NL4-3 12F
NL4-3 12R
GAC CAG GGA GAG CAT TTG TTA CAA TAG
CCT CAA TAG CCC TCA GCA AAT TGT TC
60
NL4-3 13F
NL4-3 13R
GAG CAG TGG GAA TAG GAG CTT TG
CTA ATC GAA TGG ATC TGT CTC TGT CTC
60
NL4-3 14F
NL4-3 14R
CTT TCT ATA GTG AAT AGA GTT AGG CAG GG
CAT TGG TCT TAA AGG TAC CTG AGG TG
55
NL4-3 15F
NL4-3 15R
GGA GCA ATC ACA AGT AGC AAT ACA GC
TGG AAT GCA GTG GCG CGA TCT
65
3¢-A overhangs were added by Taq-polymerase on PCR samples by
one additional PCR cycle to enable direct cloning of the PCR prod-
uct into the Topo vector, following the manufacturer's instructions
(TOPO TA cloning kit; Invitrogen). The plasmids carrying the frag-
ments of interest were purified from overnight bacterial cultures
using the Qiagen Miniprep kit. Sequencing was carried out by the
UCL Sequencing Service using the M13 primers.
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Antiretroviral activity of isoxazolidine
sulfonates and sulfonamides
We have synthesized novel series of isoxazolidines bearing two
points of diversity; at the sulfonate⁄sulfonamide, R
1, and at the
C-3 position of the heterocyclic scaffold, R
2. Initially, we tested a
small collection of 19 compounds with a range of substituents at
R
1 and R
2 for their ability to inhibit HIV infection and replication
(Table 1). The initial screen was performed using a HIV-1 based
vector that was pseudotyped with the vesicular stomatitis virus
G-protein (VSV-G) and expressed the green fluorescent protein
(GFP) (16). Human CD4+ T-lymphoid SupT1 cells were preincubated
with the compounds for 6 h, infected with the HIV-1 vector at a
multiplicity of infection (MOI) of 0.05 and analyzed by flow
cytometry 24 h later. The percentage of GFP+ cells was then plot-
ted against the compound dose. This assay allowed rapid screen
of the compound library and an accurate titration of the dose-
response curve. Compounds with IC90 values lower than 150 lM
were considered to be inhibitors of HIV infection. Of the library-
screened, three compounds, 1i, 1k and 1l, had significant anti-
retroviral activity indicating the importance of aromatic groups in
both the sulfonamide motif and directly appended to the heterocy-
clic scaffold. Compounds bearing sulfonate esters in the C-4 posi-
tion of the isoxazolidine scaffold were in general only moderately
active. Isoxazolidine 1f, bearing an allyl sulfonamide, was
observed to be ineffective and was hence included in all other
experiments as a negative control (Table 1). The most active com-
pounds, 1i, 1k and 1l, were then retested in the human CD4+ T-
lymphocytic C8166 cells, which were infected with wild-type
NL4.3 HIV-1. Cells were pretreated with the compounds for 6 h
and infected in the presence of the compounds for 24 h. Media
was changed, and cells analyzed by p24 capsid immunostaining
72 h later. Importantly, the same compounds found to be effective
against the HIV-1 vector were also inhibiting wild-type HIV-1 repli-
cation with similar IC50 and IC90 values (Table 1).
Next, we considered whether the compounds were similarly active
in cell types other than CD4+ T cells. To this end, we first tested
the compounds on several different cell lines at IC90 concentrations,
including the epithelial cell line HeLa, the embryonic fibroblastic cell
line 293T and the osteosarcoma cell line HT1080. The HIV-1 viral
vector was inhibited in all cell types, but the compounds varied in
potency in different cell lines (Figure 1A). We also tested compound
1l on another retrovirus unrelated to HIV, the murine leukemia virus
(MLV), and found it to be similarly effective (Figure 1B). The differ-
ent potency of the compounds in different cell lines and their ability
to inhibit replication of two unrelated retroviruses with similar
potency hinted at the possibility that the compounds targeted a
host factor broadly required for retrovirus replication rather than a
viral enzyme.
HIV-1 vector NL43 R1 R2
IC50/µM IC90/µMIC50/µM IC90/µM
1a 
1b  O
Br
1c 
1d 
O
1e 
1f 
O
2N
1g 
Cl
1h 
1i 
Br
1j 
1k 
Br
1l 
Cl
1m 
Br
1n 
O
2N
1o  MeO
1p 
Cl
1q 
Cl
1r 
1s 
1t  O
Br
117 225 - -
195 250 115 180
100 225 - -
85 175 105 150
>250 >250 - -
>250 >250 >250 >250
>250 >250 - -
90 >250 - -
76 100 36 70
225 >250 - -
75 130 71 105
93 150 91 175
165 230 - -
175 225 - -
>250 >250 - -
85 175 - -
80 250 - -
150 200 - -
100 200 - -
151 200 - -
C6F5O
C6F5O
C6F5O
C6F5O
N
H
EtO2C
Ph
N
H
C6F5O
C6F5O
N
H
N
H
N
H
N
H
C6F5O
N
H
N
H
N
H
N
H
N
H
HO
N
H
HO
N
H
S
R
1
N
O
R
2
O O
1
Table 1: Antiretroviral activity of isoxazolidine and isoxazole
sulfonamides.
IC50 and IC90 values of the compounds screened are shown for the
HIV-1 vector and wild-type virus, strain NL4.3. Cells were incubated
with different concentrations of compounds for 6 h prior to infec-
tions at an MOI of 0.05. SupT1 cells were utilized for the HIV-1
vector and C8166 cells for NL4.3. Infected cells were counted by
flow cytometry 24 h (HIV-1 vector) or 72 h (NL4.3) post infection by
flow cytometry. –, not tested.
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not toxic
It was important to assess whether the compounds are toxic to
exclude a non-specific antiretroviral effect. Hence, we studied the
effect of the compounds on (i) cell growth, (ii) cell viability and
(iii) cell cycle progression. To study cell growth, SupT1 cells were
incubated with the compounds at IC50 and IC90 concentrations
over a period of 48 h, and the number of viable cells was
counted every 24 h. Figure 2A shows that 1l and 1k inhibited
cell growth at IC90 concentrations after 48 h, but at 24 h cell
growth was maintained. To examine cell viability, SupT1 cells
were exposed to the compounds at IC90 and half of the IC90
concentrations for 24 h and analyzed by flow cytometry using a
double fluorescent assay to label live and dead cells. No loss of
cell viability was detected in these conditions (Figure 2B). The
same conditions were used to examine cell cycle progression by
propidium iodide staining, and aphidicolin, a DNA polymerase
inhibitor that arrests cells in the G1⁄S phase (22), was used as a
positive control. No significant changes in the cell cycle profile
were detected in cells exposed to the compounds compared to
AB
Figure 1: compounds activity in different cell types. (A) The indicated cell types were incubated with the compounds at IC90 concentra-
tions for 6 h prior to infection with the HIV-1 vector. Bars show the average percentage of infected cells relative to control (no compound
added) € average deviation. Results were compiled from two independent experiments performed in duplicate. (B) SupT1 cells were incubated
with the indicated compounds at IC90 concentrations for 6 h prior infection with an MLV vector and analyzed 24 h later by flow cytometry.
Similar results were obtained in another independent experiment.
AB
C
Figure 2: The compounds show no significant cell toxicity at the IC90 concentrations. (A) Analysis of cell growth. SupT1 cells were incubated
with the compounds at IC90 concentrations (bottom) and half the IC90 concentrations (top) and counted every 24 h. (B) Analysis of cell viability.
SupT1 cells were incubated with the indicated compounds at IC90 concentrations and half the IC90 concentrations for 30 h prior to double fluores-
cent labeling for the detection of live and dead cells by flow cytometry (for details refer to Materials and Methods). Digitonin, cells treated with
digitonin as a positive control for dead cells. Cells, samples incubated with DMSO only. (C) Cell cycle profiling. HeLa cells were incubated with the
indicated compounds at IC90 concentrations for 30 h prior to staining with PI and flow cytometry. Cells, samples incubated with DMSO only. APH,
cells incubated with aphidicolin. Values were compiled from two independent experiments performed in triplicates.
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the compounds were not toxic at the IC90 concentration for a per-
iod of 24 h, and hence their antiretroviral effect was specific. In
all further experiments conducted, cells were only exposed to the
compounds for 24 h.
Isoxazolidines inhibit the establishment of an
actively transcribing provirus
We investigated the step(s) of the HIV-1 life that were impaired
by the small compounds. The HIV-1 life cycle can be simplified
into discrete steps such as entry into cells, reverse transcription,
nuclear transport, integration into host chromosomes, transcription
and exit⁄budding (23). Exit and budding are generally considered
'late steps'. Experiments shown in Table 1 already indicated that
the compounds impaired some early step in virus replication,
because they were equally effective against the HIV-1 vector in
single-cycle assays (the vector is unable to exit or bud) and wild-
type HIV-1 in replication assays. Furthermore, results shown in
Table 1 and Figure 1 also indicated that virus entry into cells was
not the main step blocked, because infection was similarly
impaired in cells infected with a pan-tropic VSV-G-pseudotyped
vector and a wild-type NL4.3 HIV-1, which uses CD4 and CXCR4
as receptor and co-receptor, respectively (24). To examine reverse
transcription, cells were infected in the presence of the com-
pounds at IC90 concentrations and analyzed by flow cytometry and
AB
D
E
C
Figure 3: Impact of the compounds on early steps of the HIV-1 infection cycle. (A–C) SupT1 cells were incubated with compounds at IC90
concentrations for 6 h prior to infection with an HIV-1 vector, and cells were analyzed 24 h later by flow cytometry and TaqMan qPCR. (A)
Quantification of infected (GFP+) cells and viral DNA copies synthesized 24 h post infection. (B) Determination by Taqman qPCR of the ratio of
2LTRs circular DNA to linear viral DNA 24 h post infection. (C) Quantification of infected (GFP+) cells and copies of viral DNA present in cells
1 week post infection. (D) Quantification of infected (GFP+) cells 1 week post-infection; cells were exposed to raltegravir at the indicated con-
centration for 24h. (E) Viral gene expression is defective in the presence of the compounds. Human 293T cells were incubated with the com-
pounds for 6 h prior to transfection with the HIV-1 plasmid pLAI, which transcribes GFP from the wild-type LTR promoter. GFP expression was
detected 24 h post transfection by flow cytometry. Values are expressed relative to control. Control, cells incubated with DMSO only. Bars
represent the average values € SE from two independent experiments performed in duplicate.
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DNA. Synthesis of viral DNA was not significantly impaired in the
presence of 1l and was reduced by about twofold in the pres-
ence of 1k, which did not account for the much greater inhibition
of infection as detected by flow cytometry for GFP expression
(Figure 3A). This result confirmed that entry and reverse transcrip-
tion were not the main steps blocked by the compounds. Further-
more, no reduction in 2LTR circular viral DNA (a hallmark of
nuclear entry (25)) relative to total viral DNA was observed by
qPCR 24 h post infection with 1f and 1k, and a modest reduc-
tion was detected with 1l, suggesting that nuclear transport of
the viral complex was not significantly impaired (Figure 3B). To
measure HIV-1 integration into host chromosomes, cells infected
in the presence of the compounds were serially passaged for
1 week. In these conditions, un-integrated DNA is gradually lost
by dilution and degradation (25,26). In parallel experiments, infec-
tion was carried out in the presence of Raltegravir, a potent and
specific integrase inhibitor (27), which was washed out after 24 h
like the other compounds (Figure 3D). No significant reduction of
GFP and viral DNA was detected 1 week post infection in cells
treated with compounds 1l and 1k, as opposed to cells treated
with raltegravir in which GFP was reduced in a dose-dependent
way (Figure 3). These results indicated that the compounds did
not inhibit integration in a detectable way.
Next, we examined if the compounds impaired viral gene expres-
sion. Transfection of cells with a plasmid driving transcription of a
marker gene from the HIV-1 LTR is a standard method to examine
viral gene expression (28); hence, we transfected cells with pLAI D
env (a near full-length HIV-1 plasmid with a deletion in env and
encoding GFP) (29) in the presence of the compounds and measured
gene expression 24 h later by flow cytometry. Remarkably, the com-
pounds inhibited viral gene expression to a level that essentially
matched the block to infection (Figure 3E), indicating that this step
was severely impaired. To follow up on this observation, cells
chronically infected with HIV-1 LAI D env were incubated with the
compounds for 24 and 48 h, total RNA extracted and viral mRNA
quantified by Taqman RT-PCR. An aliquot of the cells was also
examined by flow cytometry to detect gene expression at the pro-
tein level. Surprisingly, viral mRNA and protein levels were not
reduced significantly by the compounds at either time-point (Fig-
ure 4). The compounds did not have a significant effect on tran-
scription of a housekeeping gene such as GADPH (Figure 4C and D);
hence, they did not broadly repress RNA polymerase II-dependent
AC
D B
Figure 4: The compounds do not inhibit steady-state levels of transcription. SupT1 cells were infected with HIV-1 LAI D env (expressing
GFP) pseudotyped with VSV-G, and compounds were added at IC90 concentrations 72 h post infection, once steady-state levels of transcription
had been reached. Aliquots of cells were analyzed 24 and 48 h after addition of the compounds by flow cytometry (to detect GFP+ infected
cells) and RT-qPCR. Infected, infected cells incubated with DMSO only. (A) Gel electrophoresis of RNA extracted from cells. RNA concentration
in each lane is approximately 100 ng⁄lL with a minimum RNA integrity of 85%. (B) Quantification of GFP-expressing cells. Bars represent the
average percentage of GFP+ cells € SE after 24 and 48 h of incubation with the compounds. Results were compiled from two independent
experiments performed in duplicate. (C) GFP and GADPH mRNA copy number measured by RT-qPCR 24 h after the addition of the compounds.
Samples incubated without RT gave undetectable signal. (D) Same as C but analysis was performed at 48 h after the addition of compounds.
Results are representative of two independent experiments.
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establishment of an actively transcribing virus rather than perturb-
ing steady-state transcription, mRNA export or translation of viral
proteins.
Antiretroviral activity depends on speciﬁc
chemical substitution pattern
Based on the data collected from out initial screening, we evalu-
ated a second-generation compound collection based on the most
active compounds from our initial screening 1i and 1k (Table 1).
Whereby, we fixed the C-4 sulfonamide varied the position, ortho
or para, and nature of a halogen substituent, F, Cl, Br or I, in the
halobenzene substituent at C-3, R
2. Interestingly, the size of the
halogen atom clearly influenced compounds' potency (Figure 5).
Thus, both iodinated isoxazolidines 1w and 1y were the most
potent in each regioisomeric series. Furthermore, compounds having
the aryl group with a halo-substitution in para position, 1u, 1v, 1i
and 1w, were generally more potent than the corresponding ortho-
substituted isomers (Figure 5).
Antiretroviral activity of isoxazole
sulfonamides
We then evaluated a related class of isoxazole sulfonamides (series
2). Based on the results obtained for the isoxazolidines 1, our
library focused on benzyl sulfonamides and isoxazoles bearing halo-
genated aromatics in the C-3 position. Although some members of
this class displayed significant antiretroviral activity, e.g. 2d, 2g
and 2i, in general as a class isoxazoles 2 showed a greater cell
toxicity and lower antiretroviral activity than the isoxazolidines 1
(Figure 6). We cannot currently, based on this limited data set, attri-
bute the increased antiretroviral activity to a particular structural
characteristic of isoxazoles 2.
Selection of a HIV-1 mutant partially resistant
to the compounds
To better understand the mechanism of action of these compounds,
we attempted to select an HIV-1 resistant strain. To this end, wild-
type NL4.3 virus was grown in C8166 cells over an extended period
of time (61 days) in the presence of compound 1k at IC25 or the
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Figure 5: The halogen atom in the aryl group R
2 determines the antiretroviral potency of the isoxazolidines 1. (A) SupT1 cells were incu-
bated with varying concentrations of compounds for 6 h prior infection with an HIV-1 vector. The number of GFP+ cells was quantified by flow
cytometry 24 h post infection. Values are expressed relative to cells incubated with DMSO only. Left shows graph of compounds with the hal-
ogen atom in para position. Right shows graph of compounds with the halogen atom in ortho position. Values are representative of two inde-
pendent experiments. (B) Structures of compounds tested in A.
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tase (RT) activity was monitored at regular intervals to detect any
virus breakthrough. In a similar assay, viruses resistant to the RT
inhibitor nevirapine (30) could be consistently selected (not shown).
Virus grown in the presence of DMSO or compound 1f reached a
peak of RT activity after 10 days in culture. A transient spike of RT
activity was detected also for the virus grown in the presence of
compound 1k at day 37. Unfortunately, RT activity was gradually
lost, although it remained above background for up to 61 days of
continuous propagation (Figure 7A). Despite several attempts, a fully
resistant virus could not be rescued. The partially resistant virus
was retested in independent assays in the presence of increasing
concentrations of compounds 1f (inactive), 1l (active with an IC50
of 90 lM), 1k (active with an IC50 of 75 lM) and 1i (active
with an IC50 of 70 lM). Partially resistant and wild-type viruses
grew equally well in the presence of compound 1f, but the partially
resistant virus showed a shift in the IC50 with compound 1l (90–
150 lM) and compound 1k (75–110 lM), but no IC50 shift was
detected with compound 1i (Figure 7B). Thus, the selected virus
was partially resistant only to the least potent compound but still
susceptible to compounds with a larger halogen atom in the aryl
group at C-4.
The resistant and the parental viruses were sequenced in parallel,
and several mutations were detected. Four mutations were present
in all clones analyzed of the partially resistant virus, but not in the
parental virus. A search of the Los Alamos HIV-1 repository
sequence database confirmed that such mutations were not poly-
morfic. One mutation was at nt 257 (positions are referred to the
HIV-1 NL4.3 reference sequence (19)) in the U3 region of the
5¢ LTR, which lies within a DNAse I hypersensitive site upstream of
nucleosome nuc-1 (31); a second mutation at nt 1441 caused a neu-
tral change in residue 86 of p24 capsid from valine to methionine;
a third mutation at nt 5167 caused a non-neutral change in residue
43 of vif from histidine to tyrosine; and a fourth mutation at nt
9016 caused a non-neutral change in residue 77 of nef from argi-
nine to isoleucine.
Discussion
We have used novel synthetic methods to obtain sulfonamide deriv-
atives with broad antiretroviral activity. Systematic analysis of the
HIV-1 life cycle showed that the small compounds inhibited an early
step of the HIV-1 life cycle coincident with the establishment of an
actively transcribing virus. It should be noted that the HIV-1 vector
transcribes its unspliced mRNA from an internal spleen focus-form-
ing virus (SFFV) promoter, not the wild-type HIV-1 LTRs (16). Because
the compounds inhibited equally well the HIV-1 vector and wild-type
HIV-1, any inhibition of gene expression mediated by the compounds
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Figure 6: Activity and toxicity of isoxazole sulfonates and sulf-
onamides. (A) Chemical structures of isoxazole sulfonamides. (BC)
SupT1 cells were incubated with three concentrations of com-
pounds for 6 h prior infection with an HIV-1 vector at an MOI of
0.05. The number of GFP+ cells and live cells was quantified by
flow cytometry and is shown relative to control. Un-infected, cells
incubated with DMSO only; infected, cells infected in the absence
of compound. (B) Proportion of GFP+ cells relative to control (top
panel) and percentage of live cells (bottom panel) for isoxazole
sulfonamides 2.
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472 Chem Biol Drug Des 2010; 75: 461–474is bound to be Tat- and Rev-independent. Moreover, the compounds
did not broadly inhibit RNA polymerase II transcription, including
viral gene transcription, at steady state nor did they suppress protein
translation. The simplest explanation for our results is that our com-
pounds interfere with some rearrangements in viral DNA structure
that are required for viral transcriptional activation or that they pre-
vent correct assembly of the transcriptional machinery on the viral
promoter (31). It is known that the proviral enhancer⁄promoter
within the HIV-1 LTR is organized in precisely positioned nucleo-
somes and nucleosome-free regions (31). The rapid removal of one
nucleosome (nuc-1), positioned at nt 465–610, is a prerequisite for
transcriptional induction of the viral promoter (31), suggesting that
specific chromatin remodeling may be necessary for provirus activa-
tion (32). Therefore, our compounds may target host factors part of
the chromatin remodeling machinery that are required for transcrip-
tional activation of several retroviral promoters, and transcriptional
activation may be a valid target for antiretroviral drug development
(32). Interestingly, a phenotye similar to the one we described here
was reported previously and was shown to be caused by repression
of the cellular sulfonation pathway (26). In the future, it will be
interesting to investigate whether the sulfonamide derivatives
described in this study inhibit the sulfonation pathway.
Structure-activity relationship (SAR) studies identified two elements
critical for antiretroviral activity in isoxazolidines 1, an aryl amide
at R
1 and a halogenated benzene at R
2 (see Table 1). Moreover, the
size of the halogen and its position in the C-3 benzene significantly
influenced potency. Evaluation of the structurally related isoxazoles
2 revealed compounds with increased cell toxicity and often
reduced antiretroviral activity compared to isoxazolidines 1. By iden-
tifying the chemical substituents critical for antiretroviral activity on
the one hand and chemical regions and substitutions increasing cell
toxicity on the other hand, the SAR results provided a good starting
point for further modifications aimed at improving potency and
specificity of the compounds.
We attempted to select for an HIV-1 strain resistant to one of
the compounds, and we could detect a spike of RT activity after
37 days of continuous propagation in the presence of 1k. How-
ever, the escape virus could not be propagated in the long term,
although low-level replication did occur until day 61 as detected
by RT enzymatic assay. It is not clear at present why the virus
releasing higher RT activity at day 37 could not be further propa-
gated. It could be attributable to some different culture conditions
inadvertently introduced or to the fact that the escape virus was
less fit in the long term. In any case, a virus was obtained that
was partially resistant to the least potent isoxazolidine 1l but
was still fully sensitive to the more potent isoxazolidine 1i. This
suggested that the virus might have evolved a greater affinity for
the host factor targeted by the compounds. Sequencing of the
partially resistant mutant virus revealed four unique mutations,
two of which were non-neutral aminoacid changes, one in vif and
one in nef. One mutation was located in the U3 region of the 5¢
LTR, which may be interesting because it maps within the DNAse
I hypersensitive site upstream of nucleosome nuc-1, which must
be removed to allow trascriptional induction (31). It will be inter-
esting in the future to introduce by site-directed mutagenesis such
mutations one by one or in combination into a wild-type HIV-1
NL4.3 molecular clone to examine their physiological role.
Although longer-term virus passaging is required to further explore
this aspect, these results suggest that small compounds target-
ing host factors may be less vulnerable to the development of
resistance.
In conclusion, using novel synthetic approaches, we have generated
new sulfonamide derivatives able to block transcriptional activation
of HIV-1 and determined the chemical regions and modifications
important for their antiretroviral activity. The availability of active
and inactive compounds with very similar chemical structures
should allow the identification of the target and lead to further
improvement of potency and specificity (13). It may also reveal
novel druggable host factors important for HIV-1 replication.
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